512 related articles for article (PubMed ID: 27418815)
21. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi.
Rogliani P; Calzetta L; Ora J; Lipsi R; Segreti A; Matera MG; Cazzola M
Eur J Pharmacol; 2015 Aug; 761():383-90. PubMed ID: 25952728
[TBL] [Abstract][Full Text] [Related]
22. Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naïve COPD patients: A pooled analysis.
Muro S; Yoshisue H; Kostikas K; Olsson P; Gupta P; Wedzicha JA
Respirology; 2020 Apr; 25(4):393-400. PubMed ID: 31339215
[TBL] [Abstract][Full Text] [Related]
23. Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD.
Buhl R; Banerji D
Int J Chron Obstruct Pulmon Dis; 2012; 7():729-41. PubMed ID: 23118536
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study.
Wang C; Sun T; Huang Y; Humphries M; Bai L; Li L; Wang Q; Kho P; Firth R; D'Andrea P
Int J Chron Obstruct Pulmon Dis; 2015; 10():57-68. PubMed ID: 25609940
[TBL] [Abstract][Full Text] [Related]
25. Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study.
Beier J; Mroz R; Kirsten AM; Chuecos F; Gil EG
Int J Chron Obstruct Pulmon Dis; 2017; 12():1731-1740. PubMed ID: 28652725
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
Buhl R; Gessner C; Schuermann W; Foerster K; Sieder C; Hiltl S; Korn S
Thorax; 2015 Apr; 70(4):311-9. PubMed ID: 25677679
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study.
Dahl R; Jadayel D; Alagappan VK; Chen H; Banerji D
Int J Chron Obstruct Pulmon Dis; 2013; 8():501-8. PubMed ID: 24159259
[TBL] [Abstract][Full Text] [Related]
28. A randomized trial to determine the impact of indacaterol/glycopyrronium on nighttime oxygenation and symptoms in patients with moderate-to-severe COPD: the DuoSleep study.
Lehmann S; Ringbæk T; Løkke A; Grote L; Hedner J; Lindberg E
Int J Chron Obstruct Pulmon Dis; 2019; 14():199-210. PubMed ID: 30666100
[TBL] [Abstract][Full Text] [Related]
29. Effects of Adding Tiotropium or Aclidinium as Triple Therapy Using Impulse Oscillometry in COPD.
Manoharan A; Morrison AE; Lipworth BJ
Lung; 2016 Apr; 194(2):259-66. PubMed ID: 26758884
[TBL] [Abstract][Full Text] [Related]
30. Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis.
Karabis A; Lindner L; Mocarski M; Huisman E; Greening A
Int J Chron Obstruct Pulmon Dis; 2013; 8():405-23. PubMed ID: 24043936
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD.
Reisner C; Pearle J; Kerwin EM; Rose ES; Darken P
Int J Chron Obstruct Pulmon Dis; 2018; 13():1965-1977. PubMed ID: 29950826
[TBL] [Abstract][Full Text] [Related]
32. Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD.
Fukushima Y; Nakatani Y; Ide Y; Sekino H; St Rose E; Siddiqui S; Maes A; Reisner C
Int J Chron Obstruct Pulmon Dis; 2018; 13():1187-1194. PubMed ID: 29695902
[TBL] [Abstract][Full Text] [Related]
33. Glycopyrronium bromide for the treatment of chronic obstructive pulmonary disease.
Riario-Sforza GG; Ridolo E; Riario-Sforza E; Incorvaia C
Expert Rev Respir Med; 2015 Feb; 9(1):23-33. PubMed ID: 25547422
[TBL] [Abstract][Full Text] [Related]
34. Bronchodilator efficacy of 18 μg once-daily tiotropium inhalation via Discair
Yildiz P; Bayraktaroglu M; Gorgun D; Secik F
Int J Chron Obstruct Pulmon Dis; 2016; 11():2859-2867. PubMed ID: 27920513
[TBL] [Abstract][Full Text] [Related]
35. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.
Greulich T; Kostikas K; Gaga M; Aalamian-Mattheis M; Lossi NS; Patalano F; Nunez X; Pagano VA; Fogel R; Vogelmeier CF; Clemens A
Int J Chron Obstruct Pulmon Dis; 2018; 13():1229-1237. PubMed ID: 29713156
[TBL] [Abstract][Full Text] [Related]
36. A novel model-based approach for dose determination of glycopyrronium bromide in COPD.
Arievich H; Overend T; Renard D; Gibbs M; Alagappan V; Looby M; Banerji D
BMC Pulm Med; 2012 Dec; 12():74. PubMed ID: 23217058
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies.
ZuWallack R; Allen L; Hernandez G; Ting N; Abrahams R
Int J Chron Obstruct Pulmon Dis; 2014; 9():1133-44. PubMed ID: 25342898
[TBL] [Abstract][Full Text] [Related]
38. Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review.
Ulrik CS
Int J Chron Obstruct Pulmon Dis; 2014; 9():331-8. PubMed ID: 24729699
[TBL] [Abstract][Full Text] [Related]
39. Exacerbation recovery patterns in newly diagnosed or maintenance treatment-naïve patients with COPD: secondary analyses of TICARI 1 trial data.
Mannino DM; Clerisme-Beaty EM; Franceschina J; Ting N; Leidy NK
Int J Chron Obstruct Pulmon Dis; 2018; 13():1515-1525. PubMed ID: 29785101
[TBL] [Abstract][Full Text] [Related]
40. Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study.
Wedzicha JA; Zhong N; Ichinose M; Humphries M; Fogel R; Thach C; Patalano F; Banerji D
Int J Chron Obstruct Pulmon Dis; 2017; 12():339-349. PubMed ID: 28176893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]